Skip to main content
SpringerLink
Log in

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer

  • Chapter
  • First Online:
Reviews on New Drug Targets in Age-Related Disorders

Part of the book series: Advances in Experimental Medicine and Biology ((PMISB,volume 1286))

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moya-Horno I, Viteri S, Karachaliou N, Rosell R (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol 10:1758834017745012. https://doi.org/10.1177/1758834017745012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E et al (2017) Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 19(4):301–314

    Article  PubMed  Google Scholar 

  3. Silva AP, Coelho PV, Anazetti M, Simioni PU (2017) Targeted therapies for the treatment of non-small-cell lung cancer: monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 13(4):843–853

    Article  PubMed  Google Scholar 

  4. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA et al (2017) Current and emergent therapy options for advanced squamous-cell lung cancer. J Thorac Oncol 13(2):165–183

    Article  PubMed  CAS  Google Scholar 

  5. Vestergaard HH, Christensen MR, Lassen UN (2018) A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol 57(2):176–186

    Article  CAS  PubMed  Google Scholar 

  6. Johnson DB, Rioth MJ, Horn L (2014) Immune checkpoint inhibitors in NSCLC. Curr Treat Options in Oncol 15(4):658–669

    Article  Google Scholar 

  7. Pirker R (2013) EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol 8(1):47–53

    Article  PubMed  Google Scholar 

  8. Evans M, O’Sullivan B, Smith M, Hughes F, Mullis T, Trim N et al (2018) Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases. Pathol Oncol Res 25(4):1401–1409

    Article  PubMed  CAS  Google Scholar 

  9. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7):397–406

    Article  CAS  PubMed  Google Scholar 

  10. Pirker R, Filipits M (2011) Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol/Hematol 80(1):1–9

    Article  Google Scholar 

  11. Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531

    Article  CAS  PubMed  Google Scholar 

  12. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Robert H et al (2007) B3-03: a randomized multicenter phase III study of cetuximab (Erbitux®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2(8):S340–S341

    Article  Google Scholar 

  13. da Cunha SG, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49–69

    Article  CAS  Google Scholar 

  14. Wood DE (2015) National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin 25(2):185–197

    Article  PubMed  Google Scholar 

  15. Masters GA, Johnson DH, Temin S (2016) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 12(1):90–93

    Article  PubMed  Google Scholar 

  16. Mazzarella L, Guida A, Curigliano G (2018) Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther 18(4):483–493

    Google Scholar 

  17. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J et al (2014) Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. Cancer Biol Ther 15(5):504–509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I et al (2017) A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget 8(9):15943–15951

    Article  PubMed  Google Scholar 

  20. Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH, Jung KS et al (2015) A phase Ib/II study of afatinib in combination with nimotuzumab in non–small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. Clin Cancer Res 22(9):2139–2145

    Article  PubMed  CAS  Google Scholar 

  21. Qi D, Cui Y, Wang Q, Huang C, Xu J, Yang Y et al (2015) A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer. J Cancer Res Ther 11(Suppl 1):C32–C37. https://doi.org/10.4103/0973-1482.163836

    Article  CAS  PubMed  Google Scholar 

  22. Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK et al (2013) A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 79(3):270–275

    Article  PubMed  Google Scholar 

  23. Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R et al (2011) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 67(4):837–845

    Article  CAS  PubMed  Google Scholar 

  24. Choi HJ, Sohn JH, Lee CG, Shim HS, Lee IJ, Yang WI et al (2011) A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 71(1):55–59

    Article  PubMed  Google Scholar 

  25. Sung H-J, Cho J-Y (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41(9):615–625

    Article  CAS  PubMed  Google Scholar 

  26. Molina R, Filella X, Auge J, Fuentes R, Bover I, Rifa J et al (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biol 24(4):209–218

    Article  CAS  Google Scholar 

  27. Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S et al (2013) A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Investig New Drugs 31(3):661–668

    Article  CAS  Google Scholar 

  28. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K et al (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17(6):1007–1013

    Article  CAS  PubMed  Google Scholar 

  29. Schiller JH, von Pawel J, Schütt P, Ansari RH, Thomas M, Saleh M et al (2010) Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5(12):1977–1985

    Article  PubMed  Google Scholar 

  30. Chigutsa E, Long AJ, Wallin JE (2017) Exposure-response analysis of necitumumab efficacy in squamous non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 6(8):560–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Thakur MK, Wozniak AJ (2017) Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma. Lung Cancer 8:13–19

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774

    Article  CAS  PubMed  Google Scholar 

  33. Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R et al (2016) Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol 27(8):1573–1579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R et al (2016) The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trial. J Thorac Oncol 11(6):808–818

    Article  PubMed  Google Scholar 

  35. Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H et al (2016) Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR-expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). Oncol Res Treat 39(9):539–547

    Article  CAS  PubMed  Google Scholar 

  36. Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK et al (2017) Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in east Asian patients with stage IV squamous non-small cell lung cancer: a subgroup analysis of the phase 3, open-label, randomized SQUIRE study. Cancer Res Treat 49(4):937–946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH et al (2017) An open-label, randomized, controlled phase II study of paclitaxel-carboplatin chemotherapy with necitumumab versus paclitaxel-carboplatin alone in first-line treatment of patients with stage IV squamous non–small-cell lung cancer. Clin Lung Cancer 18(5):480–488

    Article  CAS  PubMed  Google Scholar 

  38. Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16(3):328–337

    Article  CAS  PubMed  Google Scholar 

  39. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K et al (2008) US Food and Drug Administration approval: panitumumab for epidermal growth factor receptor–expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14(5):1296–1302

    Article  CAS  PubMed  Google Scholar 

  40. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14(2):502–508

    Article  CAS  PubMed  Google Scholar 

  41. Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K et al (2013) A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non–small-cell lung cancer. J Thorac Oncol 8(12):1510–1518

    Article  CAS  PubMed  Google Scholar 

  42. Schuette W, Behringer D, Stoehlmacher J, Kollmeier J, Schmager S, von Weikersthal LF et al (2015) CHAMP: a phase II study of panitumumab with pemetrexed and cisplatin versus pemetrexed and cisplatin in the treatment of patients with advanced-stage primary nonsquamous non–small-cell lung cancer with particular regard to the KRAS status. Clin Lung Cancer 16(6):447–456

    Article  CAS  PubMed  Google Scholar 

  43. Edelman MJ, Hu C, Le QT, Donington JS, D’Souza WD, Dicker AP et al (2017) Randomized phase II study of preoperative chemoradiotherapy±panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (stage IIIa, N2+) non–small cell lung cancer: NRG oncology RTOG 0839. J Thorac Oncol 12(9):1413–1420

    Article  PubMed  PubMed Central  Google Scholar 

  44. Spigel DR, Mekhail TM, Waterhouse D, Hadley T, Webb C, Burris HA III et al (2017) First-line carboplatin, pemetrexed, and panitumumab in patients with advanced non-squamous KRAS wild type (WT) non-small-cell lung cancer (NSCLC). Cancer Investig 35(8):541–546

    Article  CAS  Google Scholar 

  45. Wang Y, Wang H, Jiang Y, Zhang Y, Wang X (2017) A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. Biomed Pharmacother 89:875–879

    Article  CAS  PubMed  Google Scholar 

  46. Blumenschein GR, Reckamp K, Stephenson GJ, O’Rourke T, Gladish G, McGreivy J et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non–small cell lung cancer. Clin Cancer Res 16(1):279–290

    Article  CAS  PubMed  Google Scholar 

  47. Wieck MM, Spurrier RG, Levin DE, Mojica SG, Hiatt MJ, Reddy R et al (2016) Sequestration of vascular endothelial growth factor (VEGF) induces late restrictive lung disease. PLoS One 11(2):e0148323. https://doi.org/10.1371/journal.pone.0148323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Niu G, Chen X (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11(8):1000–1017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Chen XW, Sun JG, Zhang LP, Liao XY, Liao RX (2017) Recruitment of CD11b+ Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody. Oncol Lett 14(1):615–622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12):1097–1105

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718

    Article  CAS  PubMed  Google Scholar 

  52. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. New Engl J Med 355(24):2542–2550

    Article  CAS  PubMed  Google Scholar 

  53. Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M et al (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non–small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 27(9):1405–1412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E et al (2018) Randomized phase II trial of parsatuzumab (anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung cancer. Oncologist 23(6):654–e58. https://doi.org/10.1634/theoncologist.2017-0690

    Article  CAS  Google Scholar 

  55. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673

    Article  CAS  PubMed  Google Scholar 

  56. Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D et al (2017) Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 112:181–187

    Article  PubMed  Google Scholar 

  57. Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB et al (2018) Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 82(1):77–86

    Article  CAS  PubMed  Google Scholar 

  58. Gil-Bazo I (2017) Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. Transl Lung Cancer Res 6(S1):S35–S38. https://doi.org/10.21037/tlcr.2017.11.01

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2(9):846–856

    Article  CAS  PubMed  Google Scholar 

  60. Cui S, Dong L, Qian J, Ye L, Jiang L (2018) Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells. J Cancer 9(1):129–134

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Santini FC, Rudin CM (2017) Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol 10(9):935–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Passiglia F, Galvano A, Rizzo S, Incorvaia L, Listì A, Bazan V et al (2018) Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer 142(6):1277–1284

    Article  CAS  PubMed  Google Scholar 

  63. Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G (2018) Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharm 40:46–50

    Article  CAS  Google Scholar 

  64. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550

    Article  CAS  PubMed  Google Scholar 

  65. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New Engl J Med 375(19):1823–1833

    Article  CAS  PubMed  Google Scholar 

  67. Seetharamu N, Preeshagul IR, Sullivan KM (2017) New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer 8:67–78

    Google Scholar 

  68. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41

    Article  CAS  PubMed  Google Scholar 

  69. Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B et al (2017) Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer. Clin Cancer Res 23(18):5394–5405

    Article  CAS  PubMed  Google Scholar 

  70. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373(2):123–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ et al (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 7(1). https://doi.org/10.1038/s41598-017-06002-8

  73. Ilie M, Hofman P (2017) Atezolizumab in advanced non-small cell lung cancer. J Thorac Dis 9(10):3603–3606

    Article  PubMed  PubMed Central  Google Scholar 

  74. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X

    Article  PubMed  Google Scholar 

  75. Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A (2017) Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opin Biol Ther 17(6):781–789

    Article  PubMed  Google Scholar 

  76. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 377(20):1919–1929

    Article  CAS  PubMed  Google Scholar 

  77. Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M et al (2016) A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer 17(3):232–236. e231

    Article  CAS  PubMed  Google Scholar 

  78. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A et al (2016) Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer. Lancet Oncol 17(3):299–308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X et al (2016) Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 11(1):95. https://doi.org/10.1186/s13000-016-0545-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Shafique MR, Robinson LA, Antonia S (2018) Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res 10:931–940

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ et al (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18(5):599–610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Xie H, Adjei AA (2017) Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. Transl Lung Cancer Res 6(Suppl 1):S41–S43. https://doi.org/10.21037/tlcr.2017.10.15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Xu Y, Kong GKW, Menting JG, Margetts MB, Delaine CA, Jenkin LM et al (2018) How ligand binds to the type 1 insulin-like growth factor receptor. Nat Commun 9(1):821. https://doi.org/10.1038/s41467-018-03219-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Yuan J, Yin Z, Tao K, Wang G, Gao J (2018) Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy. Oncol Lett 15(1):41–47

    PubMed  Google Scholar 

  85. Humar M, Kern I, Vlacic G, Hadzic V, Cufer T (2017) Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival. Radiol Oncol 51(2):195–202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Scagliotti G, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J et al (2014) Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 26(3):497–504

    Article  PubMed  Google Scholar 

  87. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T (2014) Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non–small-cell lung cancer. J Clin Oncol 32(19):2059–2066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D et al (2009) Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 4(11):1397–1403

    Article  PubMed  PubMed Central  Google Scholar 

  89. Nakagawa T, Ohta K, Kubozono K, Ishida Y, Naruse T, Takechi M et al (2015) Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch Oral Biol 60(4):557–565

    Article  CAS  PubMed  Google Scholar 

  90. de Oliveira CC, Brizeno LAC, de Sousa FB, Mota MRL, Alves APNN (2016) Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - review. Med Oral Patol Oral Cir Bucal 21(4):e431–e439. https://doi.org/10.4317/medoral.21044

    Article  PubMed  PubMed Central  Google Scholar 

  91. Panagiotidis I, Christoulas D, Terpos E (2016) Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. Ann Transl Med 4(24):510. https://doi.org/10.21037/atm.2016.11.75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Narducci P, Bareggi R, Nicolin V (2011) Receptor activator for nuclear factor kappa B ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem 113(2):73–81

    Article  CAS  PubMed  Google Scholar 

  93. Udagawa H, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K et al (2017) Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases. J Cancer Res Clin Oncol 143(6):1075–1082

    Article  CAS  PubMed  Google Scholar 

  94. Hendriks LE, Hermans BC, van den Beuken-van MH, Hochstenbag MM, Dingemans A-MC (2016) Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non–small cell lung Cancer and bone metastases: a systematic review. J Thorac Oncol 11(2):155–173

    Article  PubMed  Google Scholar 

  95. Curioni-Fontecedro A, Husmann L, Soldini D, Stahel R (2013) Primary non-small cell lung cancer response upon treatment with denosumab. Lung Cancer 82(3):506–508

    Article  CAS  PubMed  Google Scholar 

  96. Takeno A, Yamamoto M, Notsu M, Sugimoto T (2016) Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report. BMC Endo Dis 16(1):66. https://doi.org/10.1186/s12902-016-0148-0

    Article  Google Scholar 

  97. Yassin M, Soliman A, De Sanctis V, Abdelrahman M, Aziz Bedair E, AbdelGawad M (2014) Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab 18(4):546–551

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC et al (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123(15):2936–2944. https://doi.org/10.1002/cncr.30717

    Article  CAS  PubMed  Google Scholar 

  99. Bottaro DP, Rubin JS, Faletto DL, Chan AL, Kmiecik TE, Woude GV et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251(4995):802–804

    Article  CAS  PubMed  Google Scholar 

  100. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10(10):2867–2878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. D’Arcangelo M, Cappuzzo F (2013) Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 7:61–68

    PubMed  PubMed Central  Google Scholar 

  102. Mok TSK, Geater SL, Su WC, Tan EH, Yang JCH, Chang GC et al (2016) A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in Asian patients with advanced stage pulmonary adenocarcinoma. J Thorac Oncol 11(10):1736–1744

    Article  PubMed  Google Scholar 

  103. Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445–450

    Article  CAS  PubMed  Google Scholar 

  104. Rowshanravan B, Halliday N, Sansom DM (2017) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67

    Article  PubMed  CAS  Google Scholar 

  105. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–1736

    Article  CAS  PubMed  Google Scholar 

  106. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054

    Article  CAS  PubMed  Google Scholar 

  107. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24(1):75–83

    Article  PubMed  Google Scholar 

  108. Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D et al (2016) Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol 11(9):1511–1521

    Article  PubMed  PubMed Central  Google Scholar 

  109. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895

    Article  CAS  PubMed  Google Scholar 

  110. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748

    Article  CAS  PubMed  Google Scholar 

  111. Planchard D, Barlesi F, Gomez-Roca C, Mazieres J, Varga A, Greillier L et al (2016) Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM). Ann Oncol 27(Suppl 6):vi429. https://doi.org/10.1093/annonc/mdw383.45

    Article  Google Scholar 

  112. Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS et al (2015) Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol 10(1):65–76

    Article  PubMed  Google Scholar 

  113. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L et al (2010) A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16(23):5883–5891

    Article  CAS  PubMed  Google Scholar 

  114. Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P et al (2013) A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non–small-cell lung Cancer. J Thorac Oncol 8(3):329–337

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Yunes Panahi

  2. Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Amir Hossein Mohammadzadeh

  3. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

    Behzad Behnam

  4. Herbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman, Iran

    Behzad Behnam

  5. Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Kerman University of Medical Sciences, Kerman, Iran

    Behzad Behnam

  6. Faculty of Pharmacy, Department of Pharmaceutics, University of Ahl Al Bayt, Karbala, Iraq

    Hossein M. Orafai

  7. Faculty of Pharmacy, Department of Pharmaceutics, Al-Zahraa University, Karbala, Iraq

    Hossein M. Orafai

  8. Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran

    Tannaz Jamialahmadi

  9. Faculty of Medicine, Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran

    Tannaz Jamialahmadi

  10. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  11. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  12. Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

    Amirhossein Sahebkar

Authors
  1. Yunes Panahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Hossein Mohammadzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Behzad Behnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hossein M. Orafai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tannaz Jamialahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory of Neuroproteomics Department of Biochemistry and Tissue Biology, Institute of Biology University of Campinas (UNICAMP), Sao Paulo, Brazil

    Paul C. Guest

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Panahi, Y., Mohammadzadeh, A.H., Behnam, B., Orafai, H.M., Jamialahmadi, T., Sahebkar, A. (2021). A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. In: Guest, P.C. (eds) Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology(), vol 1286. Springer, Cham. https://doi.org/10.1007/978-3-030-55035-6_3

Download citation

Publish with us

Policies and ethics

Search

Navigation